Compare JAKK & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAKK | SWKH |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Diversified Financial Services |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.1M | 175.5M |
| IPO Year | 1996 | 1999 |
| Metric | JAKK | SWKH |
|---|---|---|
| Price | $16.56 | $16.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $36.67 | $18.00 |
| AVG Volume (30 Days) | ★ 92.0K | 9.8K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.06% | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | 0.53 | ★ 1.85 |
| Revenue | ★ $574,298,000.00 | $40,149,000.00 |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | $6.54 | N/A |
| P/E Ratio | $31.14 | ★ $9.32 |
| Revenue Growth | N/A | ★ 62.38 |
| 52 Week Low | $14.87 | $13.17 |
| 52 Week High | $35.79 | $20.49 |
| Indicator | JAKK | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 58.23 |
| Support Level | $16.24 | $16.97 |
| Resistance Level | $16.93 | $17.47 |
| Average True Range (ATR) | 0.51 | 0.33 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 72.57 | 52.83 |
Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells and distributes toys and related kid-targeted consumer products, inclusive of kids indoor and outdoor furniture, costumes and various product lines in the sporting goods and home furnishings space. Its products offering include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: (i) Toys/Consumer Products and (ii) Costumes.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.